Drugmaker Merck says their experimental vaccine Stimuvax has started a Phase III clinical trial for breast cancer and lung cancer. The drug has been shown to help prime a patient's immune system to recognize and kill cancer cells. The newest study will be conducted on patients who have advanced, inoperable breast cancer, and patients who have advanced, inoperable lung cancer, researchers say.
Read moreSource: Medifocus Guidebook on: Small Cell Lung Cancer
The goals of treatment for patients with small cell lung cancer include: Remove or shrink the tumor Kill all residual cancer cells Prevent or... Read more »
Researchers have genetically altered a virus to make a vaccine that may be able to treat a variety of advanced cancers. In a recent small study, the... Read more »
Source: National Cancer Institute
Cancer Vaccines Key Points • • • Vaccines boost the immune system’s natural ability to defend the body against infection and to protect it... Read more »
According to a new study, the human papillomavirus (HPV) vaccine works for women aged 24 to 45 who aren't already infected by HPV, the virus that has... Read more »
Source: National Cancer Institute
Colorectal Cancer Research from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: NCI Fact Sheet Key Points • • • The... Read more »
Lung mass, right upper lung - chest X-ray... Read more »